These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 31339827)

  • 1. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    Muss HB; Polley MC; Berry DA; Liu H; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Kartcheske PA; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Sutton LM; Magrinat G; Parker BA; Hart RD; Grenier D; Hurria A; Jatoi A; Norton L; Hudis CA; Winer EP; Carey L
    J Clin Oncol; 2019 Sep; 37(26):2338-2348. PubMed ID: 31339827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in older women with early-stage breast cancer.
    Muss HB; Berry DA; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Becker HP; Kartcheske PA; Wheeler JD; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Magrinat G; Parker BA; Hart RD; Grenier D; Norton L; Hudis CA; Winer EP;
    N Engl J Med; 2009 May; 360(20):2055-65. PubMed ID: 19439741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
    Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
    J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
    Mallmann P; Nitschmann S
    Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
    O'Shaughnessy J; Koeppen H; Xiao Y; Lackner MR; Paul D; Stokoe C; Pippen J; Krekow L; Holmes FA; Vukelja S; Lindquist D; Sedlacek S; Rivera R; Brooks R; McIntyre K; Brownstein C; Hoersch S; Blum JL; Jones S
    Clin Cancer Res; 2015 Oct; 21(19):4305-11. PubMed ID: 26041745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
    Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
    Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
    Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
    Stockler MR; Harvey VJ; Francis PA; Byrne MJ; Ackland SP; Fitzharris B; Van Hazel G; Wilcken NR; Grimison PS; Nowak AK; Gainford MC; Fong A; Paksec L; Sourjina T; Zannino D; Gebski V; Simes RJ; Forbes JF; Coates AS
    J Clin Oncol; 2011 Dec; 29(34):4498-504. PubMed ID: 22025143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.